These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29333729)

  • 21. Biogenic nanoparticles as immunomodulator for tumor treatment.
    Cheng K; Kang Q; Zhao X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1646. PubMed ID: 32464709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved cancer immunotherapy strategies by nanomedicine.
    Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
    Froimchuk E; Carey ST; Edwards C; Jewell CM
    Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
    Chen Q; Chen M; Liu Z
    Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging nanotechnologies for cancer immunotherapy.
    Shukla S; Steinmetz NF
    Exp Biol Med (Maywood); 2016 May; 241(10):1116-26. PubMed ID: 27190253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boosting Checkpoint Immunotherapy with Biomaterials.
    Liu L; Pan Y; Zhao C; Huang P; Chen X; Rao L
    ACS Nano; 2023 Feb; 17(4):3225-3258. PubMed ID: 36746639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoengineering has arrived.
    Green JJ
    J Biomed Mater Res A; 2021 Apr; 109(4):397-403. PubMed ID: 32588490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Nanomedicine: Lessons for Immuno-Oncology.
    Sengupta S
    Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.
    Isser A; Livingston NK; Schneck JP
    Biomaterials; 2021 Jan; 268():120584. PubMed ID: 33338931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer.
    Cheng CT; Castro G; Liu CH; Lau P
    Clin Chim Acta; 2019 May; 492():12-19. PubMed ID: 30711524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response.
    Rawding PA; Bu J; Wang J; Kim DW; Drelich AJ; Kim Y; Hong S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1752. PubMed ID: 34414690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances of functional nanomaterials for cancer immunotherapeutic applications.
    Hao Y; Zhou X; Li R; Song Z; Min Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1574. PubMed ID: 31566896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adapting conventional cancer treatment for immunotherapy.
    Qiao J; Liu Z; Fu YX
    J Mol Med (Berl); 2016 May; 94(5):489-95. PubMed ID: 26910191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanotechnology platforms for cancer immunotherapy.
    Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
    Sheng J; Srivastava S; Sanghavi K; Lu Z; Schmidt BJ; Bello A; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S26-S42. PubMed ID: 28921644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinatorial drug delivery approaches for immunomodulation.
    Stewart JM; Keselowsky BG
    Adv Drug Deliv Rev; 2017 May; 114():161-174. PubMed ID: 28532690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving Cancer Immunotherapy Outcomes Using Biomaterials.
    Yan S; Luo Z; Li Z; Wang Y; Tao J; Gong C; Liu X
    Angew Chem Int Ed Engl; 2020 Sep; 59(40):17332-17343. PubMed ID: 32297434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of cancer: from vision to standard clinical practice.
    Huber CH; Wölfel T
    J Cancer Res Clin Oncol; 2004 Jul; 130(7):367-74. PubMed ID: 15067541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.